

Witness Name: Dr Brian Trevor Colvin

Statement No.: WITN3343014

Exhibits: WITN3343015 –

WITN3433016

Dated: 4<sup>th</sup> June 2021

## **INFECTED BLOOD INQUIRY**

---

### **SUPPLEMENTARY WRITTEN STATEMENT OF DOCTOR BRIAN TREVOR COLVIN**

---

I provide this additional statement to the previous request under Rule 9 of the Inquiry Rules 2006 dated 2 March 2020, in order to update my witness statement, dated 28<sup>th</sup> August 2020.

I, Dr Brian Trevor Colvin, will say as follows: -

#### **Section 1: Introduction**

1. Dr Brian Colvin. My address is known to the Inquiry Date of Birth: GRO-C 1946  
Qualifications: MA MB BChir FRCP FRCPath
2. Senior Lecturer The London Hospital Medical College – later Barts and The London Queen Mary's School of Medicine and Dentistry (Honorary Consultant Haematologist The Royal London Hospital Haemophilia Centre Director) 1977-2007
3. Member United Kingdom Haemophilia Centre Doctors (formerly Directors) Organisation (UKHCDO) 1975 (approximately) - present  
Chairman UKHCDO 1993-1996  
Honorary Membership UKHCDO awarded 2009  
Member Haemophilia Society 1970s - Present

## **Section 2: Additional statement of 4<sup>th</sup> June 2021**

4. At the end of paragraph 43 of my statement I stated that “In 1985 small quantities of heat-treated NHS concentrates became available for special situations and I published a short paper on the use of one of them”. Reference to the paper shows that my two patients were treated between June and November **1984**, not 1985.

Also, in paragraph 129, the second sentence should read “When I heard of the availability of small quantities of a small pool and “virally reduced” concentrate in Oxford in **1984** (not 1984/5), I requested a small supply to treat two patients and my experience was published (PRSE0000608).”

5. In view of the emphasis on the use of cryoprecipitate which has dominated the questions posed to clinicians during the hearings, I should have emphasised in my account of the use of cryoprecipitate in my clinical practice in paragraphs 45 and 89/90 (c) that the cryoprecipitate use reported in PRSE0003838, took place between October 1982 and July 1984.

## **Section 3: Inhibitors in Haemophilia**

6. During the session of the Infected Blood Inquiry on Friday 9<sup>th</sup> October 2020 there was a discussion on the development of inhibitors in haemophilia. The Chairman referred back to the evidence I gave earlier in the week and, for the avoidance of doubt about the incidence and prevalence of inhibitors in haemophilia, I now attach a brief statement together with a reference for the Inquiry (WITN3433015 and WITN3433016).

## **Statement of Truth**

I believe that the facts stated in this witness statement are true.

GRO-C

Signed \_\_\_\_\_

Dated \_\_\_\_4<sup>th</sup> June 2021\_\_\_\_\_

**Table of exhibits:**

<b>Date</b>	<b>Notes/ Description</b>	<b>Exhibit number</b>
18/05/2021	Letter from Dr Colvin regarding Inhibitors in Haemophilia	WITN3343015
	S. Ehrenforth et al "Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs" <i>Lancet</i> 1992; 339; 594 - 598	WITN3343016